CACLP·CISCE

The 19th China International Laboratory Medicine and Blood Transfusion Instrument Reagent Expo (CACLP), an annual IVD industry event, was held in Nanchang Greenland International Expo Center from October 26 to 28, 2022, with more than 1,400 in vitro diagnostic related enterprises from home and abroad gathering together to share the event. At this exhibition, Sciarray Biotech brought the blockbuster systemic lupus erythematosus (SLE) gene methylation precision diagnosis products and a full range of microarray products to the conference, booth number B3-1009. 

From 15:30 to 16:30 on October 27, 2022, the satellite conference for the launch of new product launch of Sciarray Biotech Systemic Lupus erythematosus Gene Methylation Products was held in Room 301, Conference Center of Greenland Primus Hotel! 

This conference has attracted the attention of many dealer partners and industry insiders, and there is an endless stream of on-site questions and consultations!

At the exhibition, Sciarray Biotech comprehensively displayed a full range of microarray products with great characteristics (a series of microarray products such as 5 joint detection chips for diabetes autoantibodies, 7 antibody microarray chips for infertility autoantibodies, and 14 antinuclear antibody profiles). At the same time, a series of IVD products such as the new product "SCIARRAY", the rapid detection platform (Helicobacter pylori rapid test, urinary iodine detection reagent, bacterial vaginosis rapid test, etc.), chemiluminescence and enzyme-linked immunoassay platform have also attracted many visitors to the exhibition to stop and discuss, and the six platforms fully demonstrate the innovative transformation ability and technical strength of Sciarray Biotechnology.

New product launch satellite meeting

From 15:30 to 16:30 on October 27, Sciarray Biotech held a satellite conference for the launch of new products of systemic lupus gene methylation products in Room 301, Conference Center, Greenland Hotel Nanchang International Expo City, which greatly broadened the participation and coverage of the conference through online live broadcast + offline on-site.
At this satellite meeting, Huang Qicheng, director of Sciarray Bio's Marketing Center, delivered an opening speech with the theme of "Development Trends and Choices of Innovative Products in the Post-epidemic Era":
In the past three years of the epidemic, all colleagues of IVD have witnessed the magnificent collection of the IVD industry, from the luminescence test of new crown nucleic acid, antibodies, antigens to traditional testing, to this year's biochemical centralized procurement in Jiangxi Province, the aftermath has not subsided, and the industry and testing practitioners are also facing unprecedented changes, adjustments and adaptations. This year's national medical insurance network is about to be launched, under the normalization of online centralized procurement and price linkage, the medical insurance bureau's execution and data sharing capabilities are becoming more and more powerful, so how should we test the situation?

In the current fee control environment, only "innovation" can break the situation! In September this year, the National Health Insurance Administration replied to Recommendation No. 4955 of the Fifth Session of the 13th National People's Congress, clearly stating that innovative medical devices are not included in the scope of centralized procurement, and leaving a certain market in addition to centralized procurement to provide space for innovative products to open up the market, which is a reward for innovators! Innovation is the future of industry development, the core engine of enterprise growth, Boston Consulting Group (BCG) divides medical device innovation into four levels: 1.0 fast forward - 2.0 fast grab - 3.0 improvement - 4.0 disruption.
Then looking at the entire IVD field, there are very few medical device products that can reach 4.0 subversive, and Sciarray's new product for systemic lupus erythematosus gene methylation detection "SLEGEN" is one of them. Of course, innovation is also a road of no return, and it also requires extraordinary hardships and efforts! To make a subversive, pioneering and industry-university-research combination innovative medical product, the difficulty is even more unimaginable. Improving life and health with innovation and quality is the original intention of our Sciarray Biotech team, focusing on meeting the real pain points of clinical and market needs, and actively and efficiently developing and promoting technologies, products and solutions that can best meet the needs of disease diagnosis is the mission of Sciarray Biologics.

Afterwards, Professor Lu Qianjin from the Institute of Dermatology of the Chinese Academy of Medical Sciences brought a rich academic feast online, and Professor Lu gave a speech on "New Technology for Diagnosis of Systemic Lupus Erythematosus (SLE)"

Systemic lupus erythematosus is an autoimmune disease that tends to occur in women during the reproductive years, often affecting vital organs such as the skin, blood, kidneys, joints, and brain. The number of patients with systemic lupus erythematosus in China exceeds one million, and its condition is complex, clinically heterogeneous, and even life-threatening. For more than a century, despite a large number of studies by scientists in various countries, there is still a lack of specific and highly sensitive diagnostic markers in the clinic, resulting in some patients with systemic lupus erythematosus unable to obtain accurate diagnosis.
Sciarray Biologics and Central South University have developed a new diagnostic marker for systemic lupus erythematosus with high specificity and sensitivity after years of hard work, which has raised the diagnosis of the disease to the genetic level for the first time in the world. The results have applied for Chinese and international invention patents, and are expected to be widely used in the clinical diagnosis and treatment evaluation of systemic lupus erythematosus. The study also found that the level of gene methylation can distinguish patients with systemic lupus erythematosus from normal people and other autoimmune diseases, which significantly improves the diagnostic reliability and accuracy of systemic lupus erythematosus, among which the specificity is more than 95% and the sensitivity is more than 90%. It can also be used to judge the efficacy of systemic lupus erythematosus.

Mr. Chen, Director of the Marketing Department of Sciarray Biologics, shared key issues such as systemic lupus erythematosus (SLE) products and application directions, clinical value, etc., and made a report on the overview, incidence, diagnosis and treatment status, clinical pain points, epigenetic basis, methylation basis and marker research progress of SLE Biologics, and led to a series of dry goods such as Sciarray Bio's systemic lupus erythematosus gene methylation products and characteristics, advantages, application scenarios, clinical value, detection principles, processes and product characteristics summary.

Conclusion

Picture: Participating in this exhibition, the technology platform and achievement accumulation of Sciarray Bio's innovation and transformation have been displayed in an all-round way, and we have gained not only the attention of Sciarray Biotech in the industry, but also felt the ardent expectations of the majority of partners and friends for Sciarray Biotech and the heavy responsibility on their shoulders. While encouraging, Sciarray Biotech will continue to use innovation and quality to improve life and health, focus on meeting the real pain points of clinical and market needs, and actively and efficiently develop and promote technologies, products and solutions that can best meet the needs of disease diagnosis. Move forward and work hard!